Search

Displaying results 3851 - 3860 of 10000 in total
  1. Drug

    RP01

    go.drugbank.com/drugs/DB05751
    Experimental

    RP01 is a novel anti-IgE immunotherapy for allergic individuals. … It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response.

  2. Drug

    Teverelix

    go.drugbank.com/drugs/DB05624
    Investigational

    A synthetic decapeptide, water-soluble Gonadotropin-releasing hormone antagonist. It has reached phase II clinical trials.

  3. Drug

    Danazol

    go.drugbank.com/drugs/DB01406
    ApprovedInvestigational

    A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsProducts: CIPLADANOGEN® 200 MG CAPSULAS
  4. Drug

    Mevastatin

    go.drugbank.com/drugs/DB06693
    Experimental

    Mevastatin or compactin is a cholesterol-lowering agent isolated from <i>Penicillium citinium</i>. … Mevastatin is a pro-drug that is activated by <i>in vivo</i> hydrolysis of the lactone ring. It has served as one of the lead compounds for the development of the synthetic compounds used today.

  5. Drug

    NCX 701

    go.drugbank.com/drugs/DB05409
    Experimental

    Nitroparacetamol (NCX-701) is a newly synthesized nitric oxide-releasing derivative of paracetamol.

  6. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. … It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.

    Categories: P-glycoprotein inhibitors, Heterocyclic Compounds, 2-Ring
  7. Drug

    Cefminox

    go.drugbank.com/drugs/DB09062
    Experimental

    Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.

    Categories: Heterocyclic Compounds, 2-Ring
  8. Drug

    EVT 302

    go.drugbank.com/drugs/DB06057
    Investigational

    EVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.

    Categories: Heterocyclic Compounds, 1-Ring
  9. Drug

    Bamifylline

    go.drugbank.com/drugs/DB13203
    Investigational

    Bamifylline is a selective A1 adenosine receptor antagonist.

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-Ring
  10. Drug

    Cerivastatin

    go.drugbank.com/drugs/DB00439
    ApprovedWithdrawn

    On August 8, 2001 the U.S. … Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2B6 Inducers